Journals / Endokrinolojide Yönelişler / 2004 / Cilt: 13 - Sayı: 6

Helicobacter pylori eradication therapy in type II diabetics

Tip II diabetiklerde Helikobakter pilori eradikasyon tedavisi

Pages
195–196
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This condition may be related in negative effects of diabet on gastrointestinal vascularity, motility and resistance to infectional agents.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, we searched the Helicobacter Pylori (HP) eradication in type II diabetics.
📊
Key Findings & Data:Patients and Methods: The study consisted of two groups containing total 44 patients who were HP (+) via upper gastrointestinal endoscopically biopsy.
💡
Conclusion & Impact:This condition may be related in negative effects of diabet on gastrointestinal vascularity, motility and resistance to infectional agents.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: In this study, we searched the Helicobacter Pylori (HP) eradication in type II diabetics. Patients and Methods: The study consisted of two groups containing total 44 patients who were HP (+) via upper gastrointestinal endoscopically biopsy. In first group there were 23 type II diabetic patients (11 men and 12 women; mean aged 48,8+ 10,6 years). In second group, there were 21, nondiabetic patients (10 men and 11 women; mean aged 49,1 ± 10,1 years). Both of groups were administered, along ten days, daily amoxicillin 1 gr (2 x .1) + clarithromycin 500 mg (2x1) + Lansoprazol 30 mg (2 x 1); triple standard therapy. After therapy on 10th week reperformed upper gastrointestinal endoscopy for searching HP positivity in all patients. Student's t test were used in statistical evaluation. Results: According to histopathological evaluation, HP eradication rate was 52,1 %, in type II diabetics, but it's 80,9 % in nondiabetics (p < 0.001). Conclusion: HP eradication rate is less in type II diabetics than nondiabetics. This condition may be related in negative effects of diabet on gastrointestinal vascularity, motility and resistance to infectional agents.

Özet

Amaç: Helikobakter Pilori eradikasyon oranı, değişik gruplarda, bazı kronik hastalıklarda değişiklikler göstermektedir. Biz bu çalışmada Tip II diabetiklerde Helikobakter Pilori (HP) eradikasyonunu araştırdık. Hastalar ve Yöntemler: Çalışma için iki grup oluşturuldu. Üst gastrointestinal endoskopik biyopsi ile HP(+) toplam 44 kişiden Tip II diabetik olan 23 hasta (11'i erkek, 12'si kadın) (ortalama yaş 48.8 ± 10.6 yU) Birinci grubu, 21 nondiabetik hasta (10'u erkek, 11 'i kadın) (ortalama yaş: 49.1 ± 10.1 yıl) ikinci grubu oluşturdu. Her iki gruba 10 gün süreyle amoksisilin 1 gr (2 x 1) + klaritromisin 500 mg (2x1) + Lansoprazol 30 mg (2 x 1) üçlü tedavi protokolü uygulandı. Tedavi sonrası 10. hafta tekrar üst GİS endoskopi yapılarak HP pozitifliği araştırıldı. İstatistiksel değerlendirme student's t testi ile yapıldı, p < 0.05 ise fark anlamlı kabul edildi. Bulgular: Histopatolojik inceleme neticesinde Tip II diabetiklerde HP eradikasyon oranı % 52.1 iken nondiabetik grupta bu oran % 80.9 idi (p < 0.001). Sonuç: Tip II diyabetiklerde HP eradikasyon oranı non-diabetiklere kıyasla daha düşüktür. Bu durum gastrointestinal sistemin vaskuler yapısında, molititesinde ve enfeksiyonlara direncinde diabetin yaptığı olumsuz etkilere bağlı olabilir.

🔖

Cite This Article

TUNA, S., CANEROĞLU, N., ÇAĞLAR, B., SANDER, E. (2022). Helicobacter pylori eradication therapy in type II diabetics. Endokrinolojide Yönelişler, Cilt: 13 - Sayı: 6, 195–196. https://ajindex.com/articles/500864

References (11)

  1. Megraud F: Epidemiology of Helicobacter Pylori. Gastroenterol Clin North Am 1993; 22: 73-88
  2. Brown L,M: Helicobacter Pylori epidemiology and routes of transmission. Epidemiol Rev 20(10; 22(2): 283-97
  3. Stolte M: Helicobacter pylori and gastric MALT Lymphoma-Lancet 1992; 339: 745-746
  4. Marshall B: Camphylobactcr Pylori: Its link to gastritis and peptic ulcer disease. Rev Infect His 1990. 12 Suppl 1: 587
  5. Asaka M. Tekeda H, Sugiyama T, Kato M: What role does Helicobacter pylori play in gastric cancer? Gastroenterology 1997; 113: s. 56-60
  6. Treiber G, Lambert JR: The effect of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 1998; 93: 1080-4
  7. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter Pylori eradication and reduced duodenal and gastric ulcer recurrence: a rewiew. Gastroenterology 1996; 110: 1244-52
  8. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirx A, Kelman A, Christine P, Knill-Jones R, Hildicth T. Symptomatic benefit from eradication Helicobacter Pylori infection in patients with nonulcer dyspepsia. N Eng J Med 1998; 339: 1869-74
  9. Blum AL, Talley NJ, O'Morain C, van Zanten SV, Labenz J, Stolte M, Louw JA: Slubbered A. Lack of the effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N England J Med 1998; 339: 1875-81
  10. Talley NJ, Janssens J, Lauritscn K, Racz I, Bulling E: Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind Placebo controlled trial with 12 month follow up. BMJ 1999; 318: 833-7
  11. Watkins PJ, Edmonds ME, Clinical features of diabetic neuropathy. Textbook of Diabetes London. Blackwell Science, 1997; 50.1-20.